Edgar Filing: CorMedix Inc. - Form 8-K

CorMedix Inc. Form 8-K June 08, 2011

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 7, 2011

CORMEDIX INC.

(Exact name of registrant as specified in its charter)

Delaware	001-34673	20-5894890
(State or other jurisdiction	(Commission	(IRS Employer
of incorporation)	File Number)	Identification No.)

745 Rt. 202-206, Suite 303, Bridgewater, NJ 08807 (Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (908) 517-9500

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- "Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- "Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- "Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Edgar Filing: CorMedix Inc. - Form 8-K

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On June 7, 2011, Bamdad Bastani, Ph.D. resigned from the Board of Directors of CorMedix Inc. in connection with his acceptance of the position of Chief Executive Officer and President of Trident Microsystems Inc. (Nasdaq: TRID), a provider of high-performance multimedia semiconductor solutions for the digital home entertainment market, in order to dedicate his full time and efforts to his new position.

Edgar Filing: CorMedix Inc. - Form 8-K

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

June 8, 2011 CORMEDIX INC.

By: /s/ Brian Lenz

Name: Brian Lenz

Title: Chief Financial Officer